Figure 1
Suggested strategy for management of TSOAC-associated bleeding. Adapted from previously published review article.34 *Preferred agent for rivaroxaban/apixaban. Possibility of benefit must be balanced against known risk of thrombosis. **Preferred agent for dabigatran. Possibility of benefit must be balanced against known risk of thrombosis. DIC, disseminated intravascular coagulation; RBC, red blood cell.
